Drug intelligence / Profile preview

dextrose monohydrate + heparin sodium

Development stage
Approved
Lead developer
Pfizer
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

**dextrose monohydrate + heparin sodium** is a sterile, nonpyrogenic solution for intravenous infusion, consisting of heparin sodium (an anticoagulant glycosaminoglycan usually derived from porcine intestinal mucosa) and hydrous dextrose USP in water for injection. Heparin inhibits reactions that lead to the clotting of blood and formation of fibrin clots both in vitro and in vivo, acting mainly by accelerating the interaction of antithrombin III with activated clotting factors (especially Factor Xa and thrombin), thereby blocking their actions[1][5][8]. Dextrose serves as an isotonic vehicle and energy source. This combination product is primarily indicated for the continuous intravenous infusion in situations requiring anticoagulant therapy, especially following initiation by IV heparin sodium. Clinical indications include prophylaxis and treatment of venous thrombosis and pulmonary embolism, atrial fibrillation with embolization, treatment of consumptive coagulopathies (DIC), prevention of clotting in surgery, and maintenance of patency in intravenous devices[1][3][5][8].

Brand names
Heparin Sodium in 5% Dextrose Injection
Other names
heparin sodium in dextrose 5% injectionheparin (porcine) in dextrose 5% injection
02

Targets

ATIII (Antithrombin III)F10 (Factor Xa)F2 (Thrombin)

Beyond the preview

Go deeper on dextrose monohydrate + heparin sodium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dextrose monohydrate + heparin sodium.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call